Interpret the arterial blood gas results (pH 7.40, pCO2 59 mm Hg, pO2 83 mm Hg, HCO3‑ 36.7 mEq/L, FiO2 0.32) in an obese patient with obstructive sleep apnea?

ABG Interpretation: Obesity Hypoventilation Syndrome (OHS)

This ABG demonstrates chronic compensated respiratory acidosis consistent with Obesity Hypoventilation Syndrome (OHS) in an obese patient with known OSA.

Primary ABG Analysis

The arterial blood gas shows:

• pH 7.40 (normal, indicating full metabolic compensation)
• pCO2 59.1 mm Hg (significantly elevated, >45 mm Hg diagnostic threshold)
• HCO3- 36.7 mEq/L (markedly elevated, indicating chronic renal compensation)
• pO2 83.2 mm Hg (mildly hypoxemic on FiO2 32%)

This represents chronic hypercapnia with complete metabolic compensation—the kidneys have retained bicarbonate to normalize pH despite persistent CO2 retention.

Clinical Diagnosis: Obesity Hypoventilation Syndrome

The combination of obesity, OSA, and awake daytime hypercapnia (pCO2 >45 mm Hg) definitively establishes the diagnosis of OHS 1. This is the most severe form of obesity-induced respiratory compromise and carries serious implications for mortality, chronic heart failure, pulmonary hypertension, and hospitalization risk 1.

Key Diagnostic Features Present:

• Elevated pCO2 (59.1 mm Hg): Exceeds the diagnostic threshold of 45 mm Hg at sea level 1
• Elevated HCO3- (36.7 mEq/L): Well above the 27 mEq/L threshold that has 85.7% sensitivity and 89.5% specificity for OHS 2. The ATS guideline specifically identifies bicarbonate >27 mEq/L as a key screening marker 1
• Mild hypoxemia: Despite supplemental oxygen (FiO2 32%), consistent with the gas exchange abnormalities in OHS 3
• Known OSA: Approximately 90% of OHS patients have coexistent OSA 1

Clinical Significance & Prognosis

This patient requires urgent intervention—OHS is associated with substantially increased morbidity and mortality compared to eucapnic OSA 4, 5. The elevated bicarbonate level (36.7 mEq/L) indicates chronic, not acute, hypoventilation, meaning this has been developing over time with progressive renal compensation.

Associated Risks:

• Pulmonary hypertension (present in 58% of OHS patients vs 9% in OSA alone) 5
• Increased cardiovascular mortality
• Higher hospitalization rates for acute-on-chronic hypercapnic respiratory failure 1
• More severe daytime sleepiness and functional impairment 3

Management Recommendations

Stable ambulatory patients with OHS should receive positive airway pressure (PAP) therapy during sleep 1.

Treatment Algorithm:

1. First-line therapy: Since this patient has known OSA (and 70% of OHS patients have severe OSA with AHI >30), initiate CPAP therapy rather than noninvasive ventilation (NIV) 1

2. If CPAP fails: Switch to NIV (bilevel PAP) if:

   • Obstructive events persist at CPAP pressures ≥15 cmH2O
   • Patient cannot tolerate high CPAP pressures
   • This represents OHS with chronic hypoventilation requiring ventilatory support 1

3. Weight loss interventions: Implement aggressive weight management targeting 25-30% body weight loss (more likely achieved with bariatric surgery) to potentially achieve OHS resolution 1

4. Follow-up monitoring: Repeat ABG after PAP initiation to document improvement in hypercapnia and assess treatment adequacy 1

Critical Pitfalls to Avoid

• Do not attribute hypercapnia to COPD alone in obese patients without confirming spirometry—OHS is frequently misdiagnosed 1
• Do not delay treatment—the bicarbonate of 36.7 mEq/L indicates this is NOT acute respiratory failure but chronic disease requiring immediate PAP therapy 1
• Do not use oxygen alone—supplemental oxygen without addressing hypoventilation can worsen hypercapnia
• Do not assume OSA treatment alone is sufficient—this patient needs specific OHS management with close monitoring of daytime blood gases 1

The normal pH despite severe hypercapnia indicates this patient has adapted chronically but remains at high risk for acute decompensation with respiratory infections or other stressors.